Kaplan-Meier estimates for cumulative survival probability of cancer patients (total study cohort) with red blood cell distribution width (RDW)>16% and below (≤16%), respectively.

<p>Survival rates were significantly lower in patients with high RDW in comparison to those with a non-elevated RDW (p<0.001). Numbers in parentheses indicate numbers of deaths in the respective group and time period.</p

Red blood cell parameters and risk of VTE in patients with solid tumors (n = 1286). Significant results are highlighted in bold.

<p>Red blood cell parameters and risk of VTE in patients with solid tumors (n = 1286). Significant results are highlighted in bold.</p

Red blood cell parameters and risk of mortality in the total study cohort (n = 1840). Significant results are highlighted in bold.

<p>Red blood cell parameters and risk of mortality in the total study cohort (n = 1840). Significant results are highlighted in bold.</p

Characteristics of the total study population, of patients who developed venous thromboembolism (VTE) and of patients who died during the observation period, as recorded at the time of entry into the study.

<p>Characteristics of the total study population, of patients who developed venous thromboembolism (VTE) and of patients who died during the observation period, as recorded at the time of entry into the study.</p

Cumulative incidence of venous thromboembolism (VTE), accounting for competing risk (death of any cause) in patients with solid tumors, grouped into patients with red cell distribution width (RDW)>16% and below (≤16%), respectively.

<p>The probability of VTE was higher in patients with high RDW (>16%) compared to patients with lower RDW (Gray's test p = 0.051). Numbers in parentheses indicate numbers of VTE events in the respective group and time period.</p

Red blood cell parameters and risk of VTE in the total study cohort (n = 1840).

<p>Red blood cell parameters and risk of VTE in the total study cohort (n = 1840).</p

Cumulative incidence of venous thromboembolism (VTE), accounting for competing risk (death of any cause) in the total study cohort, grouped into patients with red cell distribution width (RDW)>16% and below (≤16%), respectively.

<p>In competing risk analysis (accounting for death of any cause), the probability of VTE was not significantly different between patients with high RDW (>16%) and patients with non-elevated RDW (Gray's test p = 0.267). Numbers in parentheses indicate numbers of VTE events in the respective group and time period.</p